These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38232463)

  • 1. Peptidomimetics as potent dual SARS-CoV-2 cathepsin-L and main protease inhibitors: In silico design, synthesis and pharmacological characterization.
    Ciaglia T; Vestuto V; Di Sarno V; Musella S; Smaldone G; Di Matteo F; Napolitano V; Miranda MR; Pepe G; Basilicata MG; Novi S; Capolupo I; Bifulco G; Campiglia P; Gomez-Monterrey I; Snoeck R; Andrei G; Manfra M; Ostacolo C; Lauro G; Bertamino A
    Eur J Med Chem; 2024 Feb; 266():116128. PubMed ID: 38232463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual Inhibitors of Main Protease (M
    Mondal S; Chen Y; Lockbaum GJ; Sen S; Chaudhuri S; Reyes AC; Lee JM; Kaur AN; Sultana N; Cameron MD; Shaffer SA; Schiffer CA; Fitzgerald KA; Thompson PR
    J Am Chem Soc; 2022 Nov; 144(46):21035-21045. PubMed ID: 36356199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological evaluation of novel peptidomimetic inhibitors of the coronavirus 3C-like protease.
    Amblard F; LeCher JC; De R; Zhou S; Liu P; Goh SL; Tao S; Patel D; Downs-Bowen J; Zandi K; Zhang H; Chaudhry G; McBrayer T; Muczynski M; Al-Homoudi A; Engel J; Lan S; Sarafianos SG; Kovari LC; Schinazi RF
    Eur J Med Chem; 2024 Mar; 268():116263. PubMed ID: 38432056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a dual acting SARS-CoV-2 proteases inhibitor through in silico design and step-by-step biological characterization.
    Di Sarno V; Lauro G; Musella S; Ciaglia T; Vestuto V; Sala M; Scala MC; Smaldone G; Di Matteo F; Novi S; Tecce MF; Moltedo O; Bifulco G; Campiglia P; Gomez-Monterrey IM; Snoeck R; Andrei G; Ostacolo C; Bertamino A
    Eur J Med Chem; 2021 Dec; 226():113863. PubMed ID: 34571172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel nitric oxide donors are coronary vasodilators that also bind to the papain-like protease of SARS-CoV-2.
    Schmedtje JF; Ciske F; Muzzarelli KM; Assar Z
    Biomed Pharmacother; 2024 Apr; 173():116378. PubMed ID: 38492437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural Elucidation and Antiviral Activity of Covalent Cathepsin L Inhibitors.
    Falke S; Lieske J; Herrmann A; Loboda J; Karničar K; Günther S; Reinke PYA; Ewert W; Usenik A; Lindič N; Sekirnik A; Dretnik K; Tsuge H; Turk V; Chapman HN; Hinrichs W; Ebert G; Turk D; Meents A
    J Med Chem; 2024 May; 67(9):7048-7067. PubMed ID: 38630165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of the Safe and Broad-Spectrum Aldehyde and Ketoamide Mpro inhibitors Derived from the Constrained α, γ-AA Peptide Scaffold.
    Wang L; Ma C; Sacco MD; Xue S; Mahmoud M; Calcul L; Chen Y; Wang J; Cai J
    Chemistry; 2023 Jun; 29(35):e202300476. PubMed ID: 36920943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MPI8 is Potent against SARS-CoV-2 by Inhibiting Dually and Selectively the SARS-CoV-2 Main Protease and the Host Cathepsin L.
    Ma XR; Alugubelli YR; Ma Y; Vatansever EC; Scott DA; Qiao Y; Yu G; Xu S; Liu WR
    ChemMedChem; 2022 Jan; 17(1):e202100456. PubMed ID: 34242492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural and Biochemical Analysis of the Dual Inhibition of MG-132 against SARS-CoV-2 Main Protease (Mpro/3CLpro) and Human Cathepsin-L.
    Costanzi E; Kuzikov M; Esposito F; Albani S; Demitri N; Giabbai B; Camasta M; Tramontano E; Rossetti G; Zaliani A; Storici P
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compounds derived from Humulus lupulus inhibit SARS-CoV-2 papain-like protease and virus replication.
    Herzog AM; Göbel K; Marongiu L; Ruetalo N; Alonso MC; Leischner C; Busch C; Burkard M; Lauer UM; Geurink PP; Knobeloch KP; Schindler M; Fritz G; Venturelli S
    Phytomedicine; 2024 Jan; 123():155176. PubMed ID: 37976697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New anti-SARS-CoV-2 aminoadamantane compounds as antiviral candidates for the treatment of COVID-19.
    de Almeida Marques DP; Andrade LAF; Reis EVS; Clarindo FA; Moraes TFS; Lourenço KL; De Barros WA; Costa NEM; Andrade LM; Lopes-Ribeiro Á; Coêlho Maciel MS; Corrêa-Dias LC; de Almeida IN; Arantes TS; Litwinski VCV; de Oliveira LC; Serafim MSM; Maltarollo VG; Guatimosim SC; Silva MM; Tsuji M; Ferreira RS; Barreto LV; Barbosa-Stancioli EF; da Fonseca FG; De Fátima Â; Coelho-Dos-Reis JGA
    Virus Res; 2024 Feb; 340():199291. PubMed ID: 38065303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based design of pan-coronavirus inhibitors targeting host cathepsin L and calpain-1.
    Xie X; Lan Q; Zhao J; Zhang S; Liu L; Zhang Y; Xu W; Shao M; Peng J; Xia S; Zhu Y; Zhang K; Zhang X; Zhang R; Li J; Dai W; Ge Z; Hu S; Yu C; Wang J; Ma D; Zheng M; Yang H; Xiao G; Rao Z; Lu L; Zhang L; Bai F; Zhao Y; Jiang S; Liu H
    Signal Transduct Target Ther; 2024 Mar; 9(1):54. PubMed ID: 38443334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Boceprevir, Calpain Inhibitors II and XII, and GC-376 Have Broad-Spectrum Antiviral Activity against Coronaviruses.
    Hu Y; Ma C; Szeto T; Hurst B; Tarbet B; Wang J
    ACS Infect Dis; 2021 Mar; 7(3):586-597. PubMed ID: 33645977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olgotrelvir, a dual inhibitor of SARS-CoV-2 M
    Mao L; Shaabani N; Zhang X; Jin C; Xu W; Argent C; Kushnareva Y; Powers C; Stegman K; Liu J; Xie H; Xu C; Bao Y; Xu L; Zhang Y; Yang H; Qian S; Hu Y; Shao J; Zhang C; Li T; Li Y; Liu N; Lin Z; Wang S; Wang C; Shen W; Lin Y; Shu D; Zhu Z; Kotoi O; Kerwin L; Han Q; Chumakova L; Teijaro J; Royal M; Brunswick M; Allen R; Ji H; Lu H; Xu X
    Med; 2024 Jan; 5(1):42-61.e23. PubMed ID: 38181791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishing an Analogue Based In Silico Pipeline in the Pursuit of Novel Inhibitory Scaffolds against the SARS Coronavirus 2 Papain-Like Protease.
    Hajbabaie R; Harper MT; Rahman T
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33672721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omicsynin B4 potently blocks coronavirus infection by inhibiting host proteases cathepsin L and TMPRSS2.
    Li Y; Wang K; Sun H; Wu S; Wang H; Shi Y; Li X; Yan H; Yang G; Wu M; Li Y; Ding X; Si S; Jiang J; Du Y; Li Y; Hong B
    Antiviral Res; 2023 Jun; 214():105606. PubMed ID: 37076089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of small molecules with the SARS-CoV-2 papain-like protease: In silico studies and in vitro validation of protease activity inhibition using an enzymatic inhibition assay.
    Pitsillou E; Liang J; Ververis K; Hung A; Karagiannis TC
    J Mol Graph Model; 2021 May; 104():107851. PubMed ID: 33556646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An ascidian Polycarpa aurata-derived pan-inhibitor against coronaviruses targeting M
    Zhang J; Zhao L; Bai Y; Li S; Zhang M; Wei B; Wang X; Xue Y; Li L; Ma G; Tang Y; Wang X
    Bioorg Med Chem Lett; 2024 May; 103():129706. PubMed ID: 38508325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cathepsin-Targeting SARS-CoV-2 Inhibitors: Design, Synthesis, and Biological Activity.
    Flury P; Breidenbach J; Krüger N; Voget R; Schäkel L; Si Y; Krasniqi V; Calistri S; Olfert M; Sylvester K; Rocha C; Ditzinger R; Rasch A; Pöhlmann S; Kronenberger T; Poso A; Rox K; Laufer SA; Müller CE; Gütschow M; Pillaiyar T
    ACS Pharmacol Transl Sci; 2024 Feb; 7(2):493-514. PubMed ID: 38357286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-Based Design of Potent Peptidomimetic Inhibitors Covalently Targeting SARS-CoV-2 Papain-like Protease.
    Wang Q; Chen G; He J; Li J; Xiong M; Su H; Li M; Hu H; Xu Y
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.